Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with…

By Dr. Matthew Watson

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

Read the original:
Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with...

Leading Independent Proxy Advisor Glass Lewis Recommends Shareholders Vote the GREEN proxy FOR ALL MediPharm Director Nominees - June 16th, 2025
RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split - June 16th, 2025
GT Biopharma Appoints New Member to its Board of Directors - June 16th, 2025
Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress - June 16th, 2025
PolTREG Establishes U.S. Subsidiary Immuthera to Advance International Development Strategy - June 16th, 2025
Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple... - June 16th, 2025
Sunset Social Club Opens as West Hollywood’s First Luxury Cannabis Lounge for Members Only - June 16th, 2025
IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2025 - June 16th, 2025
23andMe Reaches Agreement for Sale of Business to TTAM Research Institute Following Final Round of Bidding in Court-Approved Sale Process - June 16th, 2025
Vaxart Announces Preliminary Results of Annual Meeting of Stockholders - June 16th, 2025
Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at... - June 16th, 2025
Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria - June 16th, 2025
Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R)... - June 16th, 2025
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in... - June 16th, 2025
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema... - June 16th, 2025
Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor - June 16th, 2025
Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with... - June 16th, 2025
Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease - June 16th, 2025
EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL - June 16th, 2025
Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates - June 3rd, 2025
Abivax Presents First Quarter 2025 Financial Results - June 3rd, 2025
Cronos Group Inc. to Speak at the TD Cowen 9th Annual Future of the Consumer Conference - June 3rd, 2025
Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative... - June 3rd, 2025
Ardelyx Appoints Mike Kelliher Chief Business Officer and James P. Brady Chief Human Resources Officer - June 3rd, 2025
Vaxart Announces Adjournment of Annual Meeting of Stockholders - June 3rd, 2025
Sernova Appoints Jonathan Rigby as Interim Chair - June 3rd, 2025
Neuronetics Set to Join Russell 2000® and Russell 3000® Indexes - June 3rd, 2025
Harvard Bioscience Appoints John Duke to Board of Directors - June 3rd, 2025
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 3rd, 2025
Quest PharmaTech Provides Corporate Update - June 3rd, 2025
Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting - June 3rd, 2025
Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders - June 3rd, 2025
Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568 - June 3rd, 2025
Live from ASCO 2025 | Ascentage Pharma Presents Clinical Data on Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Refractory Patients in Oral Report - June 3rd, 2025
Live from ASCO 2025 | Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors - June 3rd, 2025
argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference - June 3rd, 2025
Press Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell disease - June 3rd, 2025
Roche’s Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer - June 3rd, 2025
Addex Convenes Annual General Meeting 2025 - June 3rd, 2025
Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025 - May 26th, 2025
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences - May 26th, 2025
IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of... - May 26th, 2025
Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025 - May 26th, 2025
Syncromune® Inc. Announces Publication of Abstract on SYNC-T® Therapy SV-102 Phase 1 Data for Metastatic Prostate Cancer at ASCO 2025 Annual Meeting - May 26th, 2025
Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2 - May 26th, 2025
CHMP recommends EU approval of Roche’s Itovebi for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer - May 26th, 2025
MediPharm Labs Cautions Shareholders about Dissident Nominees’ Governance Failures at Check-Cap Ltd. - May 26th, 2025
Boundless Bio Announces Portfolio Prioritization and Runway Extension - May 26th, 2025
Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year;... - May 26th, 2025
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 - May 26th, 2025
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences - May 26th, 2025
Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q - May 26th, 2025
Zhengye Biotechnology Holding Limited Receives NASDAQ Notice Related to Late Filing of Form 20-F - May 26th, 2025
IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules - May 26th, 2025
Polyrizon Announces Receipt of Nasdaq Delisting Notice - May 26th, 2025
Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant... - May 26th, 2025
ZLNA – Issuance of shares through set-off of option exercise fee - May 26th, 2025
Guerbet : Changes in the composition of the Guerbet board of directors. - May 26th, 2025
Chair of Sernova Biotherapeutics Resigns - May 26th, 2025
Vaxart Approves Resolutions to Narrow Proposed Reverse Split Range and Proposes Reducing Authorized Shares at Future Stockholder Meeting - May 18th, 2025
Spectral Medical to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference - May 18th, 2025
Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day - May 18th, 2025
Windtree Therapeutics Reports First Quarter 2025 Financial Results and Provides Key Business Updates - May 18th, 2025
Vivex Biologics, Inc. Executive Chair Nominated for Ernst & Young LLP Entrepreneur of the Year® 2025 Florida Award - May 18th, 2025
PharmaTher Announces FDA Extends Review Period for Ketamine; New Approval Goal Date August 9, 2025 - May 18th, 2025
Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study - May 18th, 2025
Medicines for Poland: Europe Faces a Critical Choice on Medicines and Market Reform - May 18th, 2025
Conduit Pharmaceuticals Inc. Announces Reverse Stock Split - May 18th, 2025
BON Announces The Launch Of Its Postbiotic Hypoglycemic Patented Ingredient Product Series And Its Cooperation Agreement - May 18th, 2025
Transactions of Managers and Closely Associated Persons - May 18th, 2025
GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase - May 18th, 2025
Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the... - May 18th, 2025
TestoPrime Reviews Side Effects (INVESTIGATED) Is This Testosterone Booster Safe? (Ingredients, Results & Where to Buy) - May 18th, 2025
BlueSphere Bio Appoints Alan Korman, Ph.D. as Chief Scientific Officer - May 18th, 2025
75th Annual Regeneron International Science and Engineering Fair Awards Teen Scientists from Around the World More Than $9 Million in 2025 Competition - May 18th, 2025
Alvotech Announces the Outcome of the Offering in Connection with the Company’s Listing on Nasdaq Stockholm - May 18th, 2025
Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference - May 18th, 2025
Tessera Therapeutics Features New Preclinical Data Demonstrating Progress Across its In Vivo Gene Writing™ Programs and Delivery Platform at the... - May 18th, 2025
Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF... - May 18th, 2025
Coherus to Report First Quarter 2025 Financial Results on May 12, 2025 - May 6th, 2025

Global News Feed commento

Comments Off | data

June 16th, 2025

About... Dr. Matthew Watson

This author published 6272 posts in this site.

Comments are closed.

Previous post - Next post

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with…

By Dr. Matthew Watson

About... Dr. Matthew Watson

Share

Comments are closed.

Categories

Archives

Recommended Sites